A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB059872 in Subjects With Advanced Malignancies
A study for patients with AML, MDS, Myelofibrosis or solid tumors using study drug INCB059872
Sponsor: Incyte Corporation
Enrolling: Male and Female Patients
IRB Number: AAAQ7418
U.S. Govt. ID: NCT02431260
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This study is for patients with AML or myelodysplastic syndrome (MDS), SCLC ( other solid tumors, such as endocrine tumors or Myelofibrosis. In this research study we are going to determine how safe and well tolerated the study drug INCB059872 is in subjects/research participants with those types of cancer. Other reasons for this study are to study the effect INCB059872 has on the patient and the growth of their cancer, and see how INCB059872 enters and leaves the body over time (pharmacokinetics), both when taken before you have food in your stomach and after you have eatenand finally, to see how INCB059872 acts on and in the body (pharmacodynamics).
This study is closed
Matthew Ingham, MD
Do You Qualify?
Have you been diagnosed with any of the cancers mentioned above? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator